Previous close | 0.6650 |
Open | 0.6850 |
Bid | 0.6850 x N/A |
Ask | 0.7000 x N/A |
Day's range | 0.6850 - 0.6850 |
52-week range | 0.4860 - 1.2800 |
Volume | |
Avg. volume | 22 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Webinar to take place on Monday, June 5, 2023 at 12:30 PM ETNEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss the potential of foralumab in non-active secondary progressive multiple sclerosis (na SPMS) on Monday, June 5, 2023 at 12:30 PM ET. The event will feature
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing Tiziana's followers
NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego. “I was truly honored when Hanson Wade contacted me requesting that I speak at its Novel Nasal Formulation and Delivery Summit1,
There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severityIntranasal foralumab could represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ended December 31, 2022, and provided a corporate update on its lead programs in development. Gabriele Cerrone, Executive Chairman, founder and interim Chief Executive Officer of Tiziana, commented, “After announcing
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filingAlzheimer’s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Lif
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillionThe role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab dampens activated microglia NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation thera
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientifi
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhageTiziana actively exploring the clinical development of foralumab into human testing for hemorrhagic stroke NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developi
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology comp
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard Weiner will present positive data from a stud
Key Insights Tiziana Life Sciences' significant retail investors ownership suggests that the key decisions are...
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMSFirst Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMSPhase 2 protocol to be submitted to the FDA in AprilPhase 2 clinical trial expected to start in Q3 2023 NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiz
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive Officer, purchased 8,000 common shares at $0.89 per share, bringing his total holding to 38,701,237 common shares. About ForalumabActivated T cells play an important role in the inf
Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseasesNEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced
Illustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cells Further, highlights how intranasal foralumab has similar immune gene expression effects in COVID patients, MS patients and in heathy volunteersConcludes that immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases NEW Y
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the Investigational New Drug (IND) application filing for milciclib in combination with gemcitabine for non-small cell lung cancer (NSCLC). “This Phase 2 IND filing, which was achieved with minimal additional resource deployment, enhances the asset value and
The second Expanded Access patient (EA2) demonstrated additional clinical improvement in the Expanded Disability Status Scale (EDSS), a FDA recognized standard clinical outcome assessment score NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the second patient (“EA2”) with non-active secondary progre
LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months ended 30 June 2022. Development activity during the first six months ended June 2022: ForalumabTZLS-401 Received FDA approval for enrollment of a second, Secondary Progressive Multiple Sclerosis (SPMS) patient under t
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022. Highlights during the period: CLINICAL and NON-CLINICAL PROGRAMMES ForalumabTZLS-401 Announced FDA a
New York, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event, as well as at the LifeSci Corporate Access Event. Both in-person events are taking place January 9-10, 2023
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 mouse models. The study showed that intranasal foralumab, administered to the transgenic mice at doses up to 50 µg